Work

Omadacycline as a promising tetracycline alternative for treating community-acquired bacterial pneumonia: Indian experience

Year: 2025

Type: article

Abstract: Omadacycline , a novel tetracycline that has been approved for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSIs). In the present study, we evaluated the in-vitro activity of omadacycline against bacterial pathogens causing CABP. Non-duplicate isolates of methicillin susceptible Staphylococcus aureus (MSSA) (n = 105), methicillin resistant S . aureus (MRSA) (n = 102), Streptococcus pneumoniae (n = 100) and Moraxella catarrhalis (n = 102) were included. The minimum inhibitory concentration of omadacycline and other comparators were determined using the broth microdilution method. Overall, omadacycline potently inhibited MSSA (MIC 90 0.25 mg/L), MRSA (MIC 90 0.5 mg/L), S. pneumoniae (MIC 90 0.06 mg/L) and M. catarrhalis (MIC 90 0.12 mg/L) isolates. This finding reiterates that omadacycline could be a potential treatment alternative for treating severe CABP.

Source: Indian Journal of Medical Microbiology

DOI: 10.1016/j.ijmmb.2025.100833

Authors: Yamuna Devi Bakthavatchalam, Yuvasri Manokaran, Ranjan Adhiya, Kamini Walia, Balaji Veeraraghavan

Institutions: Christian Medical College, Vellore, Indian Council of Medical Research

Language: English

Topic: Antimicrobial Resistance in Staphylococcus

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,210